Sivasubramanian Baskar

National Institutes of Health — United States

Medicine · Health Sciences

24h-index2.5kcitations210works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(151), Galectins and Cancer Biology(113), Lymphoma Diagnosis and Treatment(104), Monoclonal and Polyclonal Antibodies Research(21), Immunotherapy and Immune Responses(18)

Publications210 total

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Blood·2025· 2 citedOpen Access
Supplementary Table S4 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Data from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S2 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S3 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S8 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S4 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S5 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S9 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S2 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Methods S1 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S9 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S10 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S7 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S3 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S2 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Table S8 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
Supplementary Figure S2 from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Christoph Rader(15), Adrian Wiestner(8), Suzanne Ostrand‐Rosenberg(7), Larry W. Kwak(6), Natarajan Muthusamy(5), Chi‐Ling Chiang(4), Xiaokui Mo(4), Mitch A. Phelps(4), Samuel JK Abraham(4), N Nabavi(3), Ka Yin Kwong(3), Clare Sun(3), Inhye E. Ahn(3), Carol B. Kobrin(3), Frank Frissora(3), John C. Byrd(3), John D. Isaacs(3), L H Glimcher(2), Michael G. Kennedy(2), Wyndham H. Wilson(2)